by The global prurigo nodularis treatment market size was calculated at USD 2.13 billion in 2023 and is expected to attain around USD 3.17 billion by 2033, growing at a CAGR of 4.03% from 2024 to 2033.
Key Points
- The North America prurigo nodularis treatment market size accounted for USD 870 million in 2023 and is expected to attain around USD 1,300 million by 2033.
- North America dominated the market with the major market share of 41% in 2023.
- Asia Pacific is estimated to be the fastest growing during the forecast period of 2024-2033.
- By product type, the corticosteroids segment has held the biggest market share of 37% in 2023.
- By product type, the antihistamines segment is estimated to be the fastest growing during the forecast period.
- By distribution channel type, the retail pharmacies segment has contributed more than 42% of market share in 2023.
- By distribution channel type, the online pharmacies segment is expected to be the fastest growing during the forecast period.
Prurigo nodularis is a chronic skin condition characterized by the development of itchy nodules or bumps on the skin. The prurigo nodularis treatment market encompasses various therapeutic approaches aimed at managing symptoms and improving patients’ quality of life. Treatment strategies often involve a combination of topical medications, systemic therapies, and procedural interventions tailored to each patient’s needs.
Get a Sample: https://www.precedenceresearch.com/sample/4279
Growth Factors
The prurigo nodularis treatment market is expected to witness growth due to several factors. One key factor is the increasing prevalence of prurigo nodularis globally, driven by factors such as changing lifestyles, environmental triggers, and a rise in chronic skin conditions. Additionally, advancements in medical research and technology have led to the development of innovative treatment options, expanding the therapeutic landscape for this condition.
Region Insights
The prevalence and treatment approaches for prurigo nodularis can vary by region. Developed regions with well-established healthcare infrastructures tend to have higher diagnosis rates and access to advanced treatment options. In contrast, emerging regions may face challenges related to healthcare accessibility and affordability, impacting the adoption of prurigo nodularis treatments.
Prurigo Nodularis Treatment Market Scope
| Report Coverage | Details |
| Prurigo Nodularis Treatment Market Size in 2023 | USD 2.13 Billion |
| Prurigo Nodularis Treatment Market Size in 2024 | USD 2.22 Billion |
| Prurigo Nodularis Treatment Market Size by 2033 | USD 3.17 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 4.03% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product Type and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Prurigo Nodularis Treatment Market Dynamics
Drivers
Key drivers of growth in the prurigo nodularis treatment market include increasing awareness among healthcare providers and patients about the condition, leading to improved diagnosis rates. Additionally, pharmaceutical companies’ focus on research and development aimed at novel therapies specifically targeting prurigo nodularis is driving the market forward.
Opportunities
The prurigo nodularis treatment market presents significant opportunities for pharmaceutical companies and healthcare providers. Opportunities lie in the development of targeted therapies that address the underlying mechanisms of prurigo nodularis, improving treatment efficacy and patient outcomes. Collaborations between academia, industry, and patient advocacy groups can also foster innovation and expand treatment options.
Challenges
Despite the growing interest and investment in prurigo nodularis treatment, several challenges persist. These include the complexity of diagnosing and managing prurigo nodularis due to its chronic nature and variable presentation. Additionally, treatment adherence and patient compliance with therapies can pose challenges, emphasizing the need for patient education and support programs.
Read Also: Medical Gas Market Size to Attain USD 32.47 Billion by 2033
Prurigo Nodularis Treatment Market Recent Developments
- In February 2023, Pfizer’s supplemental new drug applications (NDA) for abrocitinib (CIBINQO) was announced by the United States (U.S.) Food and Drug Application (FDA) for the treatment of serious atopic dermatitis, refractory, skin clearance, itching, severity, and disease extent for the 12 to less than 18 years of age group.
- In October 2023, new positive pruritus data for VTAMA Cream from their essential phase 3 trials was announced by a clinical-stage biopharmaceutical company, Dermavant Sciences (tapinarof). This is for children as young as two years old, and 1% of adults suffer from atopic dermatitis. It is also important to reduce itching, burning, redness, and itching.
- In February 2024, the Food and Drug Administration (FDA) accepted Galderma’s BLA (biological license application) for Nemolizumab to treat atopic dermatitis and prurigo nodularis.
Prurigo Nodularis Treatment Market Companies
- Bayer AG
- Celgene Corporation
- Glaxo Smith Kline plc
- Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)
- Johnson & Johnson Services Inc.
- Merk & Co. Inc
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Inc
- VYNE Therapeutics Inc.
Segments Covered in the Report
By Product Type
- Antihistamines
- Capsaicin Cream
- Corticosteroids
- Emollients
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
